Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma
Jan H. Beumer(Johns Hopkins University), Christopher J. Bakkenist(University of Pittsburgh)
Cited by 15
Related Papers
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer<i>in vivo</i>
|Oncotarget|2015|240
Chemoptogenetic damage to mitochondria causes rapid telomere dysfunction
|Proceedings of the National Academy of Sciences|2019|148
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
|Clinical Pharmacology & Therapeutics|2018|126
ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1
|Nature Communications|2017|104